Were numerical results disclosed?

No, the companies only announced that the primary endpoint was met without specific numbers.

How did Genmab's stock react?

Genmab shares rose after the announcement, but the percentage gain was not specified.

Genmab, AbbVie Lymphoma Combo Therapy Meets Late-Stage Trial Goal

Danish biotech Genmab and partner AbbVie said a drug combination for lymphoma achieved its primary goal in a late-stage clinical trial, sending Genmab shares higher.

June 30, 2026

1 min read

Source: The Wall Street Journal

Danish biotechnology company Genmab and its partner AbbVie announced that a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial, according to a report by The Wall Street Journal.

Trial Details

The Phase 3 trial tested a combination therapy for lymphoma. The companies did not disclose specific numerical results or trial size, but achieving the primary endpoint is a positive step toward regulatory submission.

Market Reaction

Genmab shares rose following the announcement, while AbbVie (ABBV) shares showed little change. The exact percentage gain was not specified.

What This Means for Investors

Meeting the primary endpoint in a late-stage trial increases the likelihood of a regulatory filing for the combination therapy, potentially opening a new market for Genmab and AbbVie in oncology. However, full data review by regulators is still pending.

Frequently Asked Questions

It is a combination therapy for lymphoma tested in a Phase 3 clinical trial.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.